Loading...

Purified anti-human CD4 Antibody

Pricing & Availability
Clone
OKT4 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
T4
Isotype
Mouse IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
1_OKT4_Purified_060507
Human peripheral blood lymphocytes stained with purified OKT4, followed by anti-mouse IgGs FITC
  • 1_OKT4_Purified_060507
    Human peripheral blood lymphocytes stained with purified OKT4, followed by anti-mouse IgGs FITC
  • 2_OKT4_PURE_CD4_Antibody_IHC-F_090718
    Human frozen spleen tissue slices were fixed with 4% PFA for ten minutes and blocked with 5% FBS for 30 minutes. Then, the tissue was stained with 10 µg/mL of purified anti-human CD4 antibody (clone OKT4) overnight at 4°C. On the next day, tissue was incubated with Alexa Fluor® 594 Goat anti-mouse IgG (clone Poly4053, red). Nuclei were counter-stained with DAPI (blue). The image was scanned with a 10X objective and stitched with MetaMorph® software.
Compare all formats
Cat # Size Price Quantity Check Availability Save
317401 25 µg £13
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317402 100 µg £27
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16. 

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Human peripheral T cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
IHC-F - Verified
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunohistochemistry, a concentration range of 5.0 - 10 µg/ml is suggested. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The OKT4 antibody binds to the D3 domain of CD4 and does not block HIV binding. Additional reported applications (for the relevant formats) include: immunohistochemistry of frozen sections and blocking of T cell activation. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317453 and 317454).

In a small subset of individuals, the OKT4 clone does not bind to CD4 due to polymorphisms in CD4.9

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. 76:4061.
  3. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
  4. Cicin-Sain L, et al. 2010. J. Immunol. 184:6739. PubMed
  5. Rosenzweig M, et al. 2001. J. Med. Primatol. 30:36.
  6. Linder J, et al. 1987. Am. J. Pathol. 127:1.
  7. Boche D, et al. 1999. J. Neurovirol. 5:232. (IHC)
  8. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. USA. 76:4061. (Immunogen)
  9. Lederman S, et al. 1991. Mol Immunol. 28:1171-81.
Product Citations
  1. Lu X, et al. 2021. J Exp Med. 218: . PubMed
  2. McIlwain DR, et al. 2021. Cell Host Microbe. 29:1828. PubMed
  3. Wang D, et al. 2022. Int J Oral Sci. 14:8. PubMed
  4. Feyaerts D, et al. 2022. Cell Rep Med. 3:100680. PubMed
  5. Gernoux G, et al. 2020. Mol Ther. 28:747. PubMed
  6. Brinkmann CR, et al. 2018. mSphere. 3:e00616. PubMed
  7. Son YM, et al. 2020. Eur J Immunol. 50:1067. PubMed
  8. Gao H, et al. 2021. J Virol. :. PubMed
  9. Ghosh S, et al. 2020. Cell Reports. 30(10):3434-3447. PubMed
  10. Santos R, et al. 2017. Nat Commun. . 10.1038/s41467-017-01760-5. PubMed
  11. Volchenkov R, et al. 2017. Front Immunol. 0.818055556. PubMed
  12. Delgobo M, et al. 2021. Front Immunol. 12:584538. PubMed
  13. Fletcher–Jones A, et al. 2019. Elife. 8:e44252. PubMed
  14. Harshe RP, et al. 2020. Nat Commun. 11:5894. PubMed
  15. Oberg HH, et al. 2020. J Leukoc Biol. 107:1081. PubMed
  16. Bovay A, et al. 2020. Hum Vaccin Immunother. 16:3103. PubMed
  17. Li Y, et al. 2019. Front Immunol. 0.460416667. PubMed
  18. Cobb DA, et al. 2022. J Immunother Cancer. 10:. PubMed
  19. Ma F, et al. 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.10.011. PubMed
  20. Martins MA, et al. 2017. AIDS Res Hum Retroviruses. 33:843. PubMed
  21. Perez MD, et al. 2020. Sci Rep. 10:15748. PubMed
  22. Kong R, et al. 2019. Cell. 178:567. PubMed
  23. Martins M, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006529. PubMed
  24. Wastyk HC, et al. 2021. Cell. 184(16):4137-4153.e14. PubMed
  25. Muhammad F, et al. 2020. J Autoimmun. 111:102441. PubMed
  26. Alsahafi N, et al. 2017. J Virol. 91:e00109. PubMed
  27. Li G, et al. 2022. Mol Ther Oncolytics. 24:887. PubMed
  28. Ardain A, et al. 2019. Nature. 570:528. PubMed
  29. Horn LA, et al. 2017. Oncotarget. 8:57964. PubMed
  30. Cardoso V, et al. 2017. Nature. 549:277. PubMed
  31. Majri SS, et al. 2018. J Immunol. 200:110. PubMed
  32. Matos TR, et al. 2017. J Clin Invest. 127:4031. PubMed
  33. Yang J, et al. 2020. Nat Commun. 11:4402. PubMed
  34. Lou F, et al. 2020. Immunity. 53(1):204-216.e10. PubMed
  35. Wang B, et al. 2018. Mol Ther Nucleic Acids. 0.548611111. PubMed
  36. Gernoux G, et al. 2021. Mol Ther Methods Clin Dev. 20:660. PubMed
  37. Chiou SH, et al. 2021. Immunity. 54:586. PubMed
  38. Martin E, et al. 2020. JCI Insight. :5. PubMed
  39. Seyfarth J, et al. 2018. Mol Cell Pediatr. 5:2. PubMed
  40. Prévost J, et al. 2018. Virology. 515:38:00. PubMed
RRID
AB_571962 (BioLegend Cat. No. 317401)
AB_571962 (BioLegend Cat. No. 317402)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, 55 kD
Distribution

T cell subset, majority of thymocytes, monocytes/macrophages

Function
MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor
Ligand/Receptor
MHC class II molecules, HIV gp120, IL-16
Cell Type
Macrophages, Monocytes, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Center D, et al. 1996. Immunol. Today 17:476.
2. Gaubin M, et al. 1996. Eur. J. Clin. Chem. Clin. Biochem. 34:723.

Gene ID
920 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 5    Revision Date: 04/29/2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account